Treating moderate to severe menopausal vasomotor symptoms with fezolinetant: responder analysis of the phase 3b DAYLIGHT study
Bibliographic record
Abstract
Objectives: To characterize the efficacy of fezolinetant for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause using responder analyses of VMS frequency, patient-reported outcomes (PROs) of quality of life (QOL), and time to response. Methods: Prespecified analysis of DAYLIGHT (NCT05033886), a phase 3b, randomized, double-blind, 24-week, placebo-controlled study of fezolinetant in women considered unsuitable for hormone therapy. Two approaches for responder analyses: (1) participants with change from baseline in the frequency of moderate to severe VMS of ≥50%, ≥75%, and 100%, and (2) participants who experienced a clinically meaningful within-patient change (not placebo adjusted) compared with baseline in 1, 2, or 3 specified combinations of VMS frequency and PROs: the Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b total score, Menopause-Specific QOL total score, and Menopause-Specific QOL Vasomotor domain score. P values were nominal and not controlled for multiplicity. Results: Overall, 453 participants were randomized (placebo n = 226; fezolinetant 45 mg n = 227), and 370 (81.9%) of these completed the study (n = 175; n = 195, respectively). The full analysis set comprised 452 participants (placebo n = 226; fezolinetant 45 mg n = 226). Of these, 387 (85.6%) participants completed the 24-week treatment period. The proportion of participants with ≥50%, ≥75%, and 100% reductions in VMS frequency was higher in the fezolinetant 45 mg group than placebo throughout the treatment period. Week 24 odds ratio (OR) comparisons: ≥50% reduction: fezolinetant 45 mg: 60.6% versus placebo: 46.0%; OR: 1.82; 95% CI: 1.25 to 2.65; P = 0.002; ≥75% reduction: fezolinetant 45 mg: 46.9% versus placebo: 29.6%; OR: 2.10; 95% CI: 1.43 to 3.10; P < 0.001; 100% reduction: fezolinetant 45 mg: 22.1% versus placebo: 10.6%; OR: 2.39; 95% CI: 1.42 to 4.10; P = 0.001. Reductions in VMS frequency and severity were seen as early as week 1. A greater proportion of responders was observed in the fezolinetant 45 mg group versus placebo at week 24 in all responder analyses. ORs were supportive of a beneficial effect for fezolinetant 45 mg versus placebo (OR >1) for all PROs. Conclusions: Analyses of responders in the DAYLIGHT study showed higher, clinically meaningful responder rates and supported the treatment effect of fezolinetant relative to placebo in women unsuitable for hormone therapy.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.006 | 0.004 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.002 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.004 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".